Lenvatinib

規格

417716-92-8CAS番号

970-217-1EC番号

4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamideIUPAC名

C21H19ClN4O4化学式

426.9 g/mol分子量

Lenvatinib; 417716-92-8; E7080; E-7080; E 7080; ER-203492-00; Kisplyx; 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; EE083865G2; CHEBI:85994; DTXSID50194605; 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-CHLORO-4-((CYCLOPROPYLCARBAMOYL)AMINO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-METHOXY-; lenvatinibum; 4-(3-chloro-4-(cyclopropylcarbamoylamino)phenoxy)-7-methoxyquinoline-6-carboxamide; 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-; RefChem:58936; Multi-Kinase Inhibitor E7080; DTXCID50117096; L01XE29; 970-217-1; 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; E7080 (Lenvatinib); Lenvatinib (E7080); Lenvatinib free base; 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; MFCD16038644; C21H19ClN4O4; 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide; UNII-EE083865G2; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide; CHEMBL1289601; Lenvatinib base; 4-[3-Chloro-4-(3-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide; Lenvatinib [USAN]; Lenvatinib [USAN:INN]; Lenvatini; 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-; 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; E 7080; ER 203492-00; Lenvatinib; Lenvima; LEV; 417716-92-8 (free base); Lenvatinib (Standard); LENVATINIB [MI]; LENVATINIB [INN]; Lenvatinib (USAN/INN); E7080 (Lenvatinib)?; LENVATINIB [WHO-DD]; MLS006011239; SCHEMBL864638; GTPL7426; orb1225086; orb1310532; orb3141358; SCHEMBL29349806; SCHEMBL29372021; EX-A249; WOSKHXYHFSIKNG-UHFFFAOYSA-N; GLXC-90055; HMS3244A07; HMS3244A08; HMS3244B07; HMS3654A14; HMS5079K11; Lenvatinib base - Bio-X trade mark; BDBM50331094; EBC-11343; HY-10981R; NSC755980; NSC800781; s1164; AKOS025401742; CCG-264842; CS-0109; DB09078; FC75063; NSC-755980; NSC-800781; SB16580; SDCCGSBI-0654449.P001; NCGC00263198-01; NCGC00263198-04; NCGC00263198-07; NCGC00263198-08; AC-25047; AS-16203; BL164616; BP-43663; HY-10981; SMR004702999; SY035852; DB-070219; NS00069283; SW219259-1; D09919; EN300-7418350; Q6523413; BRD-K39974922-001-02-7; BRD-K39974922-001-04-3; Z2235801899; N-(4-((6-CARBAMOYL-7-METHOXYQUINOLIN-4-YL)OXY)-2-CHLOROPHENYL)-N'-CYCLOPROPYLUREA; 6-Quinolinecarboxamide, 4-(3-chloro-4- (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-; 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)- 7-METHOXY-別名